Puma Biotechnology(US:PBYI)2020-11-06 19:09Financial Performance - Net NERLYNX revenue reached approximately $49.3 million in Q3 2020[10] - Approximately 3,600 ex-factory bottles of NERLYNX were sold in Q3 2020[15] NERLYNX Usage - Around 33% of patients in Q3 2020 started NERLYNX at a reduced dose (fewer than 6 pills per day)[18, 20] Global Expansion & Regulatory Milestones - Australia/SE Asia: Approved in Australia (March 2019), Singapore (December 2019), Brunei, Malaysia, New Zealand (Q2/Q3 2020)[23] - Israel: Launched in Q1 2020; Approved for metastatic breast cancer in Q3 2020[24] - Canada: Approved in July 2019; Metastatic sNDS accepted by HC in September 2020[24] - Greater China: Approved in Hong Kong (November 2019), China (April 2020), and Taiwan (August 2020)[24] - Latin America: Launched in Argentina (Q1 2020); Approved in Chile (Q2 2020) and Ecuador (Q3 2020); Expecting approvals in Brazil, Colombia, Mexico, and Peru in 2021[25] - Europe: Launched in Germany, United Kingdom, and Austria (Q4 2019); Launched in Sweden and approved in Switzerland (Q1 2020); Planned launch in Finland (Q4 2020)[26] - South Korea: NDA filed in October 2020[28]